4/28/2021 4:36:56 AM
Calliditas Therapeutics: FDA Grants Priority Review For Nefecon For IgA Nephropathy; Sets PDUFA Goal Date Of Sept 15
4/23/2021 4:54:51 AM
Calliditas Therapeutics: EMA Grants Accelerated Assessment Procedure For Nefecon For IgA Nephropathy
2/4/2021 3:06:58 AM
Calliditas Therapeutics Doses First Patient In Phase 3 NefIgArd Open Label Extension Study
1/21/2021 2:47:22 AM
Calliditas Therapeutics Says All 360 Patients Enrolled For Global Phase 3 Clinical Trial NefIgArd
1/20/2021 2:16:02 AM
Calliditas Announces Clinical Development Plan For Setanaxib
1/18/2021 2:40:48 AM
Genkyotex Announces Positive Phase 1 Data In In High-dose Setanaxib Trial